Clinical trials: Human Immunodeficiency Virus Type 1
Infection, Human Immunodeficiency Virus
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working properly and therefore prevents the virus…
- Trial name
- NCT00950859
- Testing
- GSK1349572 (Cohort I), GSK1349572 (Cohort II)
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 51 people
- Sponsor
- ViiV Healthcare
HIV
Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital
The main objective of the study is to assess the acceptability of a future therapeutic vaccine against HIV in patients living with HIV-1.
- Trial name
- RAVVIH (NCT02077101)
- Testing
- Questionnaire, Interview
- Where
- 3 sites in France
- Volunteers
- 220 people
- Sponsor
- Hopital Foch
HIV Infection
Dipyridamole for Immune Activation in HIV
The purpose of this study is to determine if Dipyridamole (DP) will decrease inflammation in HIV-1-infected individuals who are already on antiretroviral treatment and have a low viral load.
- Trial name
- NCT02121756
- Testing
- Dipyridamole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sharon Riddler
HIV, HIV Infections
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing…
- Trial name
- NCT01815736
- Testing
- E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF
- Where
- 167 sites in United States, Australia and 18 more
- Volunteers
- 1,443 people
- Sponsor
- Gilead Sciences
HIV Infections
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
This study will test the safety and immunogenicity of the gp120/NefTat/AS02A vaccine candidate in individuals with chronic HIV-1 infection successfully treated with HAART.
- Trial name
- NCT00117429
- Testing
- HIV gp120/NefTat/AS02A Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Marcus Altfeld, M.D., Ph.D.
HIV Infections
Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People
The purpose of this study is to determine the anti-HIV activity and safety of 3 different doses of mifepristone (also known as VGX-410 and RU486) in HIV infected people.
- Trial name
- NCT00099645
- Testing
- Mifepristone
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hypercholesterolemia
Efavirenz to Nevirapine Switch and Low-Density Lipoprotein (LDL)-Dyslipidemia
Dyslipidemia and coronary heart disease (CHD) are increasingly recognized in persons with human immunodeficiency virus (HIV) infection.
- Conditions
- HIV Infections, Hypercholesterolemia, Antiretroviral Therapy
- Trial name
- NCT00405171
- Testing
- Nevirapine
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Caen
Tuberculosis, HIV I Infection
Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa
In sub-Saharan Africa, tuberculosis (TB) is the etiology of 25-50% of bloodstream infections (BSIs) and the leading cause of sepsis among people living with HIV.
- Conditions
- Tuberculosis, HIV I Infection, Sepsis
- Trial name
- ATLAS (NCT04618198)
- Testing
- Immediate anti-TB therapy, Sepsis-specific dose anti-TB therapy
- Where
- 2 sites in Tanzania, Uganda
- Volunteers
- 437 people
- Sponsor
- University of Virginia
HIV-1-infection
LRAs United as a Novel Anti-HIV Strategy.
A translational proof of concept study in humans on the primary research question whether novel anti-human immunodeficiency virus (HIV) latency strategies, including a BAF inhibitor and a histone deacetylase inhibitor, result in…
- Trial name
- LUNA (NCT03525730)
- Testing
- Valproic Acid, Pyrimethamine
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Erasmus Medical Center
Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
Correlation Between Cytokines and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus
This study aims at correlating TNF-α, INF-γ, IL-2, IL-4, IL-10 and TGF-β values as dosed by ELISA and mRNA expression by real-time PCR with histopathological hepatic biopsy findings in individuals with HIV/HCV coinfection.
- Conditions
- Acquired Immune Deficiency Syndrome, Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, HIV Infections
- Trial name
- NCT00499434
- Where
- Brazil
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV Infections
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or…
- Trial name
- NCT00120393
- Testing
- atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
- Where
- 14 sites in United States, Canada
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
HIV Infection
Male Involvement in Antenatal Care and the Prevention Programme of Mother-to-child Transmission of HIV in Uganda
HIV /AIDS is a major public health problem in Uganda. The prevention of mother to child transmission of HIV/ AIDS (PMTCT) was launched in Uganda in November 2001 and in Mbale Hospital in May 2002.
- Trial name
- InvolvMaleUg (NCT01144234)
- Testing
- Invitation letter for male spouse, Information letter
- Where
- Uganda
- Volunteers
- 1,060 people
- Sponsor
- Centre For International Health
HIV Infections
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
The purpose of this study is to determine the safety and effectiveness of an anti-HIV drug regimen followed by treatment interruption in people recently infected with HIV.
- Trial name
- NCT00414518
- Testing
- Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir
- Where
- 3 sites in United States, Zimbabwe
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
HIV-1-infection
PRO 140 in Treatment-Experienced HIV-1 Subjects
The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in…
- Trial name
- NCT03902522
- Testing
- PRO 140
- Where
- 17 sites in United States
- Volunteers
- 6 people
- Sponsor
- CytoDyn, Inc.
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4004280 in healthy adults.
- Trial name
- NCT05163522
- Testing
- VH4004280, Midazolam
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS and VRC07-523-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in Mozambique and…
- Trial name
- ENABLE 2 (NCT07655141)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS
- Volunteers
- 73 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV Infections, HSV-2 Infection
Immunogenetic Modulators of Mucosal Protection From HIV-1
This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1…
- Trial name
- Kinga (NCT03701802)
- Where
- Kenya
- Volunteers
- 812 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults
To expand the safety information regarding MN rsgp 120/HIV-1 formulated with QS21 or alum. To evaluate the immunogenicity of low doses of MN rsgp 120/HIV-1 formulated with QS21 or alum.
- Trial name
- NCT00000853
- Testing
- rgp120/HIV-1MN
- Where
- 3 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines.
- Trial name
- NCT02463227
- Testing
- VRC01
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention, HIV Infections
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
To date, the majority of microbicide research has focused on the assessment of the safety and effectiveness of vaginal microbicides used for the prevention of HIV transmission via the vaginal compartment.
- Trial name
- RMP02-MTN006 (NCT00984971)
- Testing
- Tenofovir, Open label tenofovir tablet
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CONRAD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.